ArticlePersonalized medicine2015
Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology.
Article in Personalized medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Real-world application of comprehensive genomic profiling for gynecological malignancies: a multicenter observational study.International journal of clinical oncology · 2024Observational
- Readiness to Accept Genetic Testing for Personalized Medicine: Survey Findings on the Role of Socio-Demographic Characteristics, Health Vulnerabilities, Perceived Genetic Risk and Personality Factors.Journal of personalized medicine · 2022Article
- Emerging genetic biomarkers in lung adenocarcinoma.SAGE open medicine · 2022Review
- Patient and public understanding of the concept of 'personalised medicine' in relation to cancer treatment: a systematic review.Future healthcare journal · 2021Review
- Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?Personalized medicine · 2019Article
- Current landscape of personalized medicine adoption and implementation in Southeast Asia.BMC medical genomics · 2018Article
- The price of whole-genome sequencing may be decreasing, but who will be sequenced?Personalized medicine · 2017Article
- What are people willing to pay for whole-genome sequencing information, and who decides what they receive?Genetics in medicine : official journal of the American College of Medical Genetics · 2016Article
- Developing a Discrete Choice Experiment Instrument for Evaluating Patients' Preferences in Precision Oncology.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
aimsKnowledge of consumer perspectives of personalized medicine (PM) is limited. Our study assessed consumer perspectives of PM, with a focus on oncology care, to inform industry, clinician and payer stakeholders' programs and policy. MATERIALS &
methodsA nationally representative survey of 602 US consumers' ≥30 years old explored familiarity, perspectives and expected value of PM.
resultsMost (73%) respondents have not heard of 'personalized medicine,' though after understanding the term most (95%) expect PM to have a positive beneft. Consumer's willingness to pay is associated with products' impact on survival, rather than predicting disease risk. If testing indicates consumers are not candidates for oncology therapies, most (84%) would seek a second opinion or want therapy anyway.
conclusionsUnderstanding heterogeneity in consumer perspectives of PM can inform program and policy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.